From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium.

Last Updated: Wednesday, October 12, 2022

There is a wide dose range for tisagenlecleucel, which has shown strong complete response for patients up to the age of 26 with B-cell acute lymphoblastic leukemia (B-ALL). This article discusses impact of a higher dose on tisagenlecleucel efficacy and associated toxicity.

Blood Advances
Advertisement
News & Literature Highlights
Advertisement
Advertisement